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Abstract
Background: Influenza virus infection activates NF-B and is a general prerequisite for a productive influenza virus
infection. On the other hand, non-structural protein 1 (NS1) suppresses this viral activated NF-B, presumably to
prevent expression of NF-B mediated anti-viral response. NS1 proteins of influenza A viruses are divided into two
groups, known as allele A and allele B. The possible functional relevance of this NS1 division to viral pathogenicity
is lacking.
Findings: The ability of NS1 protein from two avian influenza subtypes, H6N8 and H4N6, to inhibit NF-B
promoter activation was assessed. Further, efforts were made to characterize the genetic basis of this inhibition. We
found that allele A NS1 proteins of H6N8 and H4N6 are significantly better in preventing dsRNA induced NF-B
promoter activation compared to allele B of corresponding subtypes, in a species independent manner.
Furthermore, the ability to suppress NF-B promoter activation was mapped to the effector domain while the RNA
binding domain alone was unable to suppress this activation. Chimeric NS1 proteins containing either RNA binding
domain of allele A and effector domain of allele B or vice versa, were equally potent in preventing NF-B
promoter activation compared to their wt. NS1 protein of allele A and B from both subtypes expressed efficiently
as detected by Western blotting and predominantly localized in the nucleus in both A549 and MiLu cells as shown
by in situ PLA.
Conclusions: Here, we present another aspect of NS1 protein in inhibiting dsRNA induced NF-B activation in an
allele dependent manner. This suggests a possible correlation with the virus’s pathogenic potential.
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Introduction
Within hours of host-pathogen interaction, the type 1
interferons (IFNs), an essential arm of innate immune
response, are induced to initiate a range of antiviral pro-
cesses. The binding of dsRNA, produced as a viral by-
product (or administered externally such as poly I:C) to
helicases or toll-like receptors (TLR), initiates a series of
events culminating in the activation of two kinase com-
plexes: TANK-binding kinase 1-inhibitor of kappa B-
kinase ε (TBK1-IKK-ε)a n dI K K - a/b/g [1]. TBK1-IKK-ε
phosphorylates interferon regulatory factor 3 and 7
(IRF3 and IRF7) while IKK-a/b/g phosphorylates and
hence activates nuclear factor-B( N F - B) transcription
factor. Activated NF-B translocates to the nucleus
where it induce the transcription of IFN-a and IFN-b as
well as other pro-inflammatory cytokines together with
ATF2/c-Jun (AP-1), p300 and CBP [2]. NF-B consists
of a family of transcription factors that play indispensa-
ble roles in mediating inflammation, immune responses
to pathogen infection, proliferation, apoptosis, and other
cellular activities [3]. Because of the essential role of
NF-B in stimulation of IFN-a/b synthesis, many
viruses have evolved different strategies to subvert this
system. The non-structural protein 1 (NS1) of influenza
A viruses is one of best example having ability to pre-
vent NF-B activation.
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activates the NF-B and exhibit higher levels of replica-
tion in cells where NF-B is pre-activated, suggesting
that a NF-B signalling pathway is a general prerequisite
for a productive influenza virus infection [4]. Kumar et
al., [5], made further clarifications that NF-B signalling
is intimately involved in the influenza vRNA synthesis.
On the contrary, viral NF-B activation is partially sup-
pressed by the NS1 protein of influenza virus, presum-
ably to prevent an overshooting expression of IFN-b.
Thus, in the context of an influenza virus infection NF-
B appears to have a supportive function for viral repli-
cation that is dominant over its antiviral activity. The
NS1 protein of influenza viruses consists of two
domains: RNA binding domain (1-73 aa) and effector
domain (74-230/237 aa). The N-terminal RNA binding
domain is mainly responsible for interaction with RNA
of several species whereas the C-terminal effector
domain primarily mediates interactions with cellular
proteins but also facilitates stabilization of the RNA
binding domain [6].
Based on their amino acid sequences, NS1 proteins of
influenza A viruses are divided into two groups, termed
as allele A and allele B. There is little information avail-
able for the possible functional relevance of this differ-
ence to viral pathogenicity. However, recently we
observed that allele A and B NS1s differ in their abilities
to inhibit IFN-b promoter activation [7]. It has been
demonstrated that H7N1 (A/FPV/Rostock/34), if carry-
ing allele B of highly pathogenetic H5N1 (A/Goose/
Guangdong/96), replicate more efficiently in human and
mouse cell lines than wild-type H7N1 [8], which indi-
cates that the NS1 protein is an essential determinant of
influenza virus pathogenesis. The present study focuses
on the abilities of allele A and B NS1 proteins to inhibit
NF-B promoter in cultured cells line.
Materials and methods
The NS1 genes from four viruses belonging to different
subtypes (H6N8 and H4N6), each containing both allele
A and B were cloned in a mammalian expression vector
pcDNA3.1+ (Invitrogen). These isolates were named
H6N8-A (Allele A, A/mallard/Sw/412/05, EU518721)
H6N8-B (Allele B, A/mallard/Sw/418/05, EU518722),
H4N6-A (Allele A, A/mallard/Sw/818/05, EU518757)
and H4N6-B (Allele B, A/mallard/Sw/795/05,
EU518749). The chimeric NS1s were constructed as fol-
low. The RNA binding domain (amino acids 1-73) of
H6N8-A and effector domain (amino acids 74-230) of
H6N8-B constitute H6N8 chiNS1 A/B and the RNA
binding domain (amino acids 1-73) of H6N8-B and the
effector domain (amino acids 74-230) of the H6N8-A
constitute the H6N8 chiNS1 B/A. The RNA binding
domains (H6N8-A-RNA and H6N8-B-RNA) and
effector domains (H6N8-A-ED and H6N8-B-ED) of
each allele were also cloned in pcDNA3.1+. The inserts
in all the clones were confirmed by sequencing and
expression ability was checked by TNT (TNT
® T7
Quick Coupled Transcription/Translation System, Pro-
mega) with
35S radiolabeling.
A549 cells, a type II alveolar epithelial cell line from
human adenocarcinoma (ATCC, CCL 185), and mink
lung cells (MiLu) were maintained as described [7]. The
day before transfection, 24-well plates were seeded with
~2.5 × 10
4 cells per well. A 0.450 μgo fe a c hr e p o r t e r
plasmid (pNF-B-Luc, containing an NF-B promoter)
and either NS1 expression plasmid or empty pcDNA3.1
+ were transfected with FuGENE6 (Roche) at a ratio of
1:3 per well. Twenty-four hours post-transfection, the
cultures were stimulated by adding 10 μg/ml poly I:C
(dsRNA) (Invivogen). Twenty-four hours post-stimula-
tion, the cells were lysed using ONE-Glo™ Luciferase
Assay System (Promega) and the lysates were subjected
to Wallac Victor
2™ 1420 multilabel counter (Wallac
Sverige AB) for luminescence. The plasmid pTA-Luc
was transfected as a negative control for the estimation
of background level of reporter gene activity and sub-
tracted from all the values. The empty pcDNA3.1+ plas-
mid was transfected as a negative control and
designated as mock treated. Each transfection experi-
ment was repeated at least three times.
To check the expression of NS1 protein in the cells, in
situ proximity ligation assay (PLA) was performed with
the Duolink in situ PLA kit (Olink Biosciences). Wes-
tern blotting was applied to check the total expression
of NS1 protein, as we reported before [7].
Results and discussion
The NS1 protein of influenza A viruses mediates resis-
tance to the eukaryotic immune system for the efficient
replication of viruses even in the presence of a func-
tional anti-viral system. This property of NS1 has been
well characterized in different studies [6,9]. In the pre-
sent study, we expanded this notion by comparing the
capacities of allele A and B NS1 proteins from two
avian influenza subtypes to confer NF-B promoter sup-
pressive properties. Notably, these viruses were basically
identical regarding other viral proteins except for the
NS gene segment.
In an initial experiment, 24 well plate was co-trans-
fected with pNF-B-Luc along with either NS1 expres-
sion plasmid for H6N8-A, H6N8-B, H4N6-A, H4N6-B
or empty vector (mock treated) or left untreated (pNF-
B cont.). Relative luciferase activity was calculated 24
hours post-dsRNA stimulation. The A549 cells trans-
fected with pNF-B-luc and stimulated with dsRNA
showed high activation of NF-Bp r o m o t e ra n dw a ss e t
to 100%. With the addition of NS1 from either of
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activation (Figure 1A). Although, the level of inhibition
of NF-B promoter was evident for both alleles (A and
B), surprisingly, it was significantly higher in allele A
(~80%) compared to allele B (H6N8-B = 30% and
H4N6-B = 40%) (p < 0.05). The non-stimulated set of
same transfections showed non-specific background
readings.
T h er e s u l t so ft h er e p o r t e r assay proposed that NS1
proteins are involved in differential blocking of signal
transduction pathways that lead to activation of the NF-
B promoters. Next, hypothesizing that these roles
might be species-specific, we further examined this
pathway in mink lung cells (MiLu). A corresponding
picture appeared to that of A549 cells, where both allele
A were consistently better in blocking the induction of
NF-B promoter compared to allele B NS1 protein of
both subtypes. Allele B has shown an inhibition of 46%
in H6N8 and 37% in H4N6 subtype of influenza virus
and allele A has shown an inhibition of 84% and 80% in
H6N8 and H4N6 compared to pNF-B control, respec-
tively (Figure 1B).
At this point, we were able to conclude that allele A is
significantly more potent in inhibiting dsRNA induced
NF-B promoter than allele B NS1 proteins. However,
we were interested to see whether this apparent limited
inhibition by allele B NS1 might be due to an insuffi-
cient expression of NS1 protein leading to weaken its
function. The whole A549 cell lysate was prepared after
transfection of NS1 constructs from both alleles of
H6N8 and H4N6, and subjected to Western blotting. As
it is clear in Figure 2A, NS1 protein from all the isolates
were expressed in high quantity and the level of allele A
NS1 was comparable to NS1 protein of allele B. Nuclear
localization of NS1 protein has been demonstrated as an
essential character for the interaction of NS1 with the
cleavage and polyadenylation specificity factor 30
(CPSF30) [10]. Furthermore, it has recently been high-
lighted that cellular expression pattern of NS1 protein is
directly related to function of NS1 protein [11,12]. To
pursue for these answers and to see the in situ expres-
sion of NS1 protein from both subtypes and both alleles,
in situ PLA, a highly sensitive technique, was applied.
The same experimental set-up was followed as that of
Western blotting and instead of lysing the cells, 12
hours post-NS1 transfection cells were fixed and pro-
cessed for PLA. As expected and consistent with Wes-
tern blotting, a high expression of NS1 was observed for
both subtypes and for both alleles. Moreover, at this
time point, NS1 predominantly accumulated in the
Figure 1 Allele A and B NS1 proteins of avian influenza A viruses differentially block the dsRNA-induced expression of NF-B
promoter in A549 and MiLu cells. (A) A549 cells were transiently co-transfected with NF-B luciferase reporter plasmid, and vector encoding
NS1 from H6N8-A, H6N8-B, H4N6-A, H4N6-B or empty pcDNA3.1+ vector (mock treated) or left un-transfected (cells). 24 hours post transfection,
cells were stimulated with dsRNA (+) or left un-stimulated (-). 24 hours post induction, cell extracts were prepared and luciferase activity was
measured using the ONE-Glo™ Luciferase Assay System (Promega) following the manufacturer’s Instructions. The values were normalized and
pNF-B cont. was set to 100%. (B) MiLu cells were transfected as described for A549 cells. All the conditions were maintained for MiLu cells as
that of (A). Error bars indicate standard deviations. The data shown are representative for three experiments with transfections performed in
duplicate. * indicates a significant difference as determined by the student’s t-test, with p-values of < 0.05.
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There was no detectable difference between alleles in
terms of NS1 production as measured by the quantifica-
tion of expressed NS1 proteins using BlobFinder soft-
ware (data not shown). Thus, the results indicated that
the low inhibition of NF-B promoter in the presence
of allele B NS1 protein was not due to a difference in
allele B NS1 protein expression and accumulation in the
cells.
Next, the genetic basis of inhibition of NF-B promo-
ter by NS1 from H6N8 allele A and B was investigated.
For this purpose, the RNA binding domain and the
effector domain from allele A and B of H6N8 (H6N8-A-
RNA, H6N8-A-ED, H6N8-B-RNA and H6N8-B-ED)
were constructed (a schematic diagram of these con-
structs is presented in Figure 3A). In a first round of
experiments, NF-B promoter was induced in A549
cells with dsRNA, in the presence of expression plas-
mids for RNA and effector domain of both allele A and
B from H6N8. As shown in Figure 3B, the RNA binding
domain from both allele A and B did not support NF-
B promoter inhibition and was non-significant when
compared to positive control. On the contrary, the effec-
tor domain from both allele A and B led to the signifi-
cant suppression of NF-B promoter activation (~70%,
when compared to pNF-B cont.) (p < 0.05). In MiLu
cells, a pattern corresponding to that of A549 cells was
observed (Figure 3C) where the effector domain inhibit
NF-B promoter whereas the RNA binding domain
lacks this ability. These results indicated that the ability
to block dsRNA induced NF-B signaling is mapped
into the effector domain and that the RNA binding
domain alone is unable to block NF-B promoter activ-
ity in both A549 and MiLu cells. Previous studies have
indicated that the effector domain of NS1 protein is
mainly involved in regulation of cellular activities by
protein-protein interaction but is also essential for the
dimerization and stability of RNA domain [6,10,13-15].
Consistent with these results, it is also likely that the
lack of effector domain in NS1 protein influences the
Figure 2 Expression patterns of allele A and allele B NS1 proteins in subcellular compartments in A549 and MiLu cells. (A) A549 cells
were transfected with vector encoding NS1 from H6N8-A, H6N8-B, H4N6-A, H4N6-B or empty pcDNA3.1+ vector (mock treated). 24 hours post-
transfection cells were lysed and subjected to Western blotting and probed with anti-NS1 and b-actin antibodies. (B) A549 and MiLu cells were
transfected with vector encoding NS1 from H6N8-A, H6N8-B, H4N6-A, H4N6-B. 18 hours post transfection, cells were fixed and processed for in
situ PLA, as recommended.
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RNA domain, which affects the function in the suppres-
sion of NF-B promoter activation.
To further prove this notion, two chimeric NS1s were
constructed containing either RNA binding domain of
allele A and effector domain of allele B (H6N8 chiNS1
A/B) and vice versa (H6N8 chiNS1 B/A). Cell transfec-
tion was performed in A549 cells as outlined before
with the difference that chimeric NS1 from both allele
A and B were used. Interestingly, NF-B promoter inhi-
bition was reversed in both chimeric NS1 and was
comparable to their wild type (wt) (Figure 3B). This
ability of chimeric NS1 was reproducible in MiLu cells
and was non-significant when compared to correspond-
ing wt NS1 protein. Taken together, these data demon-
strated that the two domains are probably functionally
interactive in a co-operative manner to result in their
overall NF-B promoter inhibition. It is also to observe
that within RNA binding domain, a unique motif
(
21RFADQELG
28 in alleles A and
21LLSMRDMC
28 in
allele B) may have biological relevance, which warrant
further investigation. Moreover, allele A NS1 proteins
Figure 3 Impact of RNA binding domain and effector domain of NS1 protein on dsRNA induced NF-B promoter activity in A549 and
MiLu cells. (A) A schematic presentation for the construction of the RNA binding domain, the effector domain from both alleles of H6N8 and
chimeric NS1s. (B) A549 cells were transiently co-transfected with NF-B luciferase reporter plasmid, and vector encoding NS1 from H6N8-A,
H6N8-B, H6N8-A-RNA, H6N8-A-ED, H6N8-B-RNA, H6N8-B-ED, H6N8 chiNS1 A/B, H6N8 chiNS1 B/A or empty pcDNA3.1+ vector (pNF-B cont.) or
left un-transfected (cells). 24 hours post transfection, cells were stimulated with dsRNA, cell extracts were prepared and luciferase activities were
measured using the ONE-Glo™ Luciferase Assay System (Promega). The values were normalized and pNF-B cont. was set to 100%. (C) All the
conditions in MiLu cells transfection were maintained as practiced in (B). Error bars indicate standard deviations. The data shown are
representative for three experiments with transfections performed in duplicate. * indicates a significant difference as determined by the student’s
t-test, with p-values of < 0.05.
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both H6N8 and H4N6 subtypes. These amino acid dif-
ferences most likely reflect differences in the respective
protein function and would be interesting to study in
terms of the biological significance in the context of
viral infections.
Conclusions
In conclusion, the results of this study demonstrated
that NS1 proteins from avian influenza A viruses (H6N8
and H4N6 subtypes) have the ability to inhibit NF-B
promoter activation and suggest a possible correlation
with the virus’s pathogenic potential. Mapping of the
NS1 protein domains involved in inhibition of NF-B
promoter showed that NS1 devoid of RNA binding
domain still exhibited property of NF-B promoter inhi-
bition. Conversely, RNA binding domain alone loses this
inhibitory activity. However, for full elucidation, further
experiments involving fusion of dimerization domain to
that of RNA binding domain are required. Moreover,
the full length NS1 protein is functionally interactive
and can efficiently block NF-B promoter activation
regardless of RNA binding domain (either of allele A or
allele B). Apart from NF-B signaling, allele A and B
NS1 protein from both subtypes were expressed predo-
minantly in nucleus but also in cytoplasm in transfected
human A549 and MiLu cells. On the basis of this work,
we presented another dimension of NS1 protein in inhi-
biting dsRNA induced NF-B activation that this char-
acter of NS1 is allele dependent.
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